is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
:
The 19th annual CPhI Pharma Awards recognises companies and individuals who are driving the pharmaceutical industry forward through innovative products, solutions and technologies.
The Awards are open to all Pharmaceutical and Biopharmaceutical companies engaged in the design, development, manufacture, production and distribution of large and small molecule drug products. Shortlisted entries and winners will be celebrated on the first night of the CPhI Worldwide event in Frankfurt, bringing together the pharma industry for a night of networking and celebration.
The Awards are free to enter, we must receive your entry by the 17th of June 2022
This award is designed to recognise innovation in technologies, products, processes, and services to combat the impact of COVID-19 on individuals, patients, healthcare professionals and communities. Including but not limited to the development and manufacture of potential vaccines, drug products and medical equipment and the introduction of services, solutions and resources to provide support to those effected by the pandemic.
Criteria:
Innovation
How does the entry demonstrate innovation and resourcefulness in response to the pandemic?
Purpose and Outcomes
Does it achieve its purpose? Does it offer benefits to the audience it was designed for? *
Problem-solving
How does it address the impact of COVID-19? Does it do so in an effective way?
Competitive Advantage
How does the entry demonstrate going above and beyond or a collaborative approach in a time of crisis?
* Given the short timeframes for response to the COVID-19 pandemic, we understand that many products or solutions will not yet have regulatory approval. Please submit as much evidence and support for your entry as is feasibly possible.
Innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients (APIs) including, but not limited to, synthesis, characterization, formulation, scale-up, software and database development, bulk manufacturing.
Criteria:
Innovation
Does the entry introduce a new idea, device, method or Formulation novelty to the market?
Purpose
Does it achieve its purpose? Does it offer benefits to the audience it was designed for
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive
Advantage Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, processes, and services related to the formulation of drug products including, but not limited to, excipients, finished dose, OTC, novel software and databases, process development, resolving formulation challenges such as solubility/ bioavailability enhancement, drug targeting or controlled release, solving stability issues such as protein aggregation, etc.
Please note: to be eligible for this category, the activity must have taken place between
Jan 2021 - August 2022
Criteria
Innovation
Does the entry introduce a new idea, device, method, or novelty to the market?
Purpose
Does it achieve its purpose? Does it offer benefits to the audience it was designed for?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, processes, and services for the manufacture of solid, semi-solid, parenteral, inhalation, or other dosage drugs including, but not limited to, equipment, manufacturing processes, facilities, process controls, and continuous manufacturing.
Criteria
Innovation
Does the entry introduce a new idea, device, method, or novelty to the market?
Features
Does the product have interesting or important part(s), qualities, abilities, improved attributes?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, solutions, processes, and services related to primary, tertiary and secondary packaging of finished drug forms, routes of administration and drug delivery devices Including, but not limited to, inhalers, auto-injectors, vials, syringes, patches, combination products, tamper-proof packaging, child-safety packaging, labelling, intelligent packaging, and fill-finish.
Criteria
Innovation
Does the entry introduce a new idea, device, method or novelty to the market?
Features & Purpose
Does the product have interesting or important part(s), qualities, abilities, improved attributes? Does it achieve what it was intended to achieve? Does it offer benefits to the audience it was designed for?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in digital technologies, products, processes, initiatives, and services which drive value in pharmaceutical development and improve patient outcomes. Including but not limited to advanced and predictive analytics, Artificial Intelligence, automation, patient-centric solutions for improved experience and adherence, track and trace, remote monitoring, medical devices, and wearables.
Criteria
Innovation
Does the entry introduce a new idea, device, method, process, or service to the market?
Purpose
Does it achieve what it was intended to achieve? Does it offer benefits to the audience it was designed for?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, processes, and services for ensuring the safe handling and tracking of drug substances, raw materials, and finished drug products including, but not limited to, supply chain, audits, temperature-controlled logistics, transport services, track and trace, shipping containers, and distribution channels.
Criteria
Innovation
Does the entry introduce a new idea, device, method, or service to the market?
Purpose
Does it achieve what it was intended to achieve? Does it offer benefits to the audience it was designed for?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
This award recognizes sustainable development in the Pharmaceutical industry and innovative initiatives for improving outcomes for patients, employees, the environment, and wider community. Including but not limited to, initiatives to minimize environmental impact, waste reduction, energy & utility saving solutions, sustainable and collaborative product development, innovative and sustainable use of resources, social outreach, employee training and mentoring programs, fair employee working policies, diversity and inclusion initiatives.
Criteria
Implementation
Does the process of implementing the initiative include all the activities that need to be done to effectuate actual change?
Achievements
Has the entry/project performed with positive outcomes and high success rates?
Positive Outcomes to Stakeholders
Did the entry/project provide good results to whoever was involved in or affected by a course of action of the respective company?
Future
Does the entry/project provide an opportunity for continuity or expansion?
Innovation in technologies, products, processes, and services designed to aid and ensure that bio/pharma companies comply with standards, rules, and guidance documents established by regulatory authorities including, but not limited to, consulting services, development of consortia and industry groups, reference standards, educational programs, and software and IT, technologies, and equipment.
Criteria
Innovation
Does the entry introduce a new idea, device, method, or service to the market?
Process Excellence
Does the product or service offer an improved process, leading to better outcomes and results?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
C-Suite Executives of SME, Large Pharma/Biopharma or service providers are eligible for nomination. Attributes to be considered include, but are not limited to, financial performance, product performance, global reach, leadership skills, management capability, charitable initiatives, sustainability, regulatory compliance, profitability, vision, marketing, acquisitions, corporate strategy, and financing.
Criteria
Dynamism
Is the nominee an exemplary leader with a strong desire to achieve – are they compelling, powerful, progressive?
Lifetime Achievements
Has the CEO achieved or accomplished sustained growth, driven improved performance, implemented robust strategies, engaged staff and customers in their current role or throughout the course of their career?
Leadership Qualities
Has the CEO consistent personal strengths and attributes that makes he or she an extraordinary leader?
Contribution to the Wider Industry
Is the CEO committed to the development of the pharma industry - be in the form of donating goods, funding, time, market insights business intelligence, new lines of business?
The CPhI Awards prides itself on its Judging Panel, which is comprised of independent, senior industry experts
from around the world, each chosen for their knowledge, objectivity and credibility.
Bikash has over 30 years of experience in design and development of pharmaceutical, biotechnology, medical device and IVD products. He has successfully commercialized over a dozen products in his career. Bikash has held senior management positions in several firmsprior to joining Pharmatech. He is a certified Lead Assessor and Lean Six Sigma Master Black Belt and a frequent speaker at industry conferences.
He is a member of the USP National Advisory Committee for API's and Excipients, LSIT Technical Advisory Board and The Stem Cell Partnering Advisory Board. Bikash currently provides recurring editorials to both Pharmaceutical Manufacturing and Controlled Environments magazine as an industry thought leader and is a member of their editorial advisory board. He is a member of cPHl's Expert Industry Panel and a member of the RFID Alliance with expertise in the effect ive applica tion of se cu rity and RFID in the pharmace utica l su pply ch ain. He has designed and built biotech facilities globally and has established global supply chain frameworks for both large and small organizations. He holds a BS in Biochemistry from University of California San Diego and a BS in Chemical Engineering from University of California San Diego.
Duncan Emerton, PhD currently holds the position of Director, Custom Intelligence & Analytics at Informa Pharma Intelligence. A global expert in biosimilars and the pharmaceutical/biotech space, Dr.Emerton is also a well-known speaker and thought-leader with an established reputation within the healthcare markets Informa Pharma Intelligence serves. Dr. Emerton has more than 20 years of experience in the pharmaceutical industry, spanning roles in non-clinical and clinical R&D, sales, marketing, medical affairs, strategic consulting and business analysis. Most recently, Duncan was at FirstWord Group, where he was responsible for all syndicated disease analysis across a wide range of therapy areas, including respiratory, autoimmune, neurology, rare diseases and oncology.
Over 25 years pharmaceutical experience in Boehringer Ingelheim, including roles in Quality, local sourcing (chemical and Pharmaceutical plants), Global sourcing (Chemical, APIs, CMOs, packaging components),
Corporate EHS&S (Senior EHS&S manager, 3rd party auditing program) and Global 3PM Chemicals Manager.
Currently I am in a group to manage the supply of outsourced/ purchased APIs (as well as strategic Starting Materials and Intermediates for our Chemical Manufacturing) for BI’s Pharmaceutical manufacturing Network. I am also Corporate EHS&S auditor to our sites and to our third party.
I am the PSCI (Pharmaceutical supply chain initiative) BI representative since 2013. Currently co-chair of the Communications committee and also part of other committees like AMR/PIE, Audit, …
I have a PhD in Chemistry from the University Autonoma of Barcelona (UAB) and an MBA from Universidad Pompeu Fabra of Barcelona.
I live in Sant Cugat del Vallés, a village nearby Barcelona (Spain). I’m married with 4 kids and my interests include soccer (supporter of FC Barcelona), gardening and riding my mountain bike (at least twice a week).
Fiona Barry, MA, is the Associate Editor of PharmSource, responsible for PharmSource’s editorial content and publication of PharmSource’s Trend Reports, monthly Bio/Pharmaceutical Outsourcing Reports, and quarterly Emerging Market Outsourcing Reports. Fiona previously worked as an investigative journalist for GlobalData’s drug development news service, formerly BioPharm Insight, reporting scoops on clinical trials, contract pharma, rare diseases, and women’s health. She is also an experienced financial journalist and a frequent expert speaker at pharmaceutical industry conferences. Fiona worked for several years as a reporter at William Reed Business Media’s French office, breaking global manufacturing, regulatory, and outsourcing news for the biopharmaceutical industry for in-PharmaTechnologist, Outsourcing-Pharma, and BioPharmaReporter. She holds an MA in English and a BA in English and Philosophy from the University of Bristol, UK and works in GlobalData’s London office.
Dr. Chauhan is an Associate Professor in Pharmaceutical Sciences at Creighton University, NE, USA; with a research lab working in the area of developing novel drug delivery systems for poorly soluble compounds. He completed his PhD from MCPHS University, Boston, MA. He had published more than 25 peer reviewed article, five book chapters and presented around 50 posters in national and international conferences. He serves as reviewer and editorial board in many reputed pharmacy journals. He is a member of American Association of Pharmaceutical Scientist (AAPS) and American Chemical Society (ACS).
Mayur is an
accomplished leader with over 18 years of innovative pharma digital health and
medical device development experience. He advises pharmaceutical companies on
digital health innovation, technology strategy, product development, regulatory
and commercialisation aspects. Mayur has led a wide range of development
programmes in PA and his past employments. He has a strong track record in
leading development of innovative devices and techniques. Mayur has helped PA’s
clients to address some of the most stringent technical needs and challenges.
Holds a BSc in Applied Biology with Quality Management from Waterford Institute of Technology and an MSc Regulatory Affairsfrom The University of Wales. Co-Founderof Shorla Pharma, a speciality pharmaceutical company developing innovative oncology products that deliver a major contribution to patient care. Previously held senior positions in EirGen Pharma and OPKO Health Inc in Quality Assurance, Research and Development, and Regulatory Affairs. Extensive experience in drug development and commercialisation for EU, US & ROW. Key areas of expertise include generic and new human and veterinary drug applications, bioequivalence study design and execution, target animal safety studies and orphan drug designation.
Led numerous regulatory inspections including FDA, HPRA and SFDA. ManagedIND’s, INAD’s & pre-development meetings with FDA. Member of the Organisation for Professionals in Regulatory Affairs (TOPRA) and Module leader for MSc. Regulatory Affairs (Medicines) University of Hertfordshire, Regulatory Strategy for Established Active Substances.
Annual attendee at American Society for Clinical Oncologists (ASCO) annual meeting and Harvard Business School (HBS) annual healthcare conference.
Awards: Shortlisted nominee for TOPRA Horizon award (2016) Network Ireland – Businesswoman of the Year Tipperary Emerging New Business (2019) Linkedin profile: https://www.linkedin.com/in/orlaith-ryan-69332b6b/
Dr Pascale Gauthier is Pharmacist with research works (master of Biopharmacy) on ‘New gelification method for vegetal oils’, specific master (DEA) in Pharmacokinetics ‘Pharmacokinetic study of antihypertensive drug and its metabolites after single and repeated dose’ and a PhD in Pharmaceutical Technology on ‘Rotogranulation process used for manufacture of spheres’.
She was involded in several patents, international publications (Int Journ of Cosm Sc, STP Pharma Pratiques, Pharm Dev Techn, Therapeutic Delivery, Journ of Pers Med., Doses) and invited speaker in different international events (Glatt TTC, Visiongain, PackVision, ADF, Pharmapack, Informa sessions on ‘drug development’, Formulations Strategies and Drug Delivery Summit). She is a member creation of PharmaDesign, and invited in the scientific committee of panel experts for ‘I love pack since 1947’ Exhibition of WorldPack in Paris. Since 1996 she is associated Pharmacist in a Pharmacy and in charge of Marketing and Design courses in the Faculty of Pharmacy of Clermont-Ferrand.
Wayne Weiner is
the principal and founder of Pharmatech Solutions LLC (PTS), a specialty
consultancy providing strategic planning, M&A advisory, and business
development services for the pharmaceutical, nutrition, and personal care
industries. Wayne has been engaged in over 30 transactions, with total closed deal
value of ~$5 Bn.
Prior to founding
PTS in 2017, Wayne held Vice President Strategy and Corporate Development roles
for DSM pharmaceutical Products (“DPP”, a business unit of Royal DSM N.V.) and
Patheon (acquired in 2017 by Thermo Fisher Scientific), one the industry’s
leading pharmaceutical custom manufacturing organizations. In these assignments
he played a key role in multiple transactions, including the $700M merger of
DPP with Patheon in 2014.
Wayne also held
Vice President Sales and Marketing positions for DPP’S North American
pharmaceutical contract manufacturing business, and for Synthon Chiragenics
Corporation, a leading supplier of specialized pharmaceutical intermediates. In
each assignment, he drove new business growth through the implementation of
strategic, customer focused sales initiatives.
Wayne was an
American Cancer Society post-doctoral fellow at Columbia University in New
York. He earned his Ph.D. in chemistry from the University of California
Berkeley, and B.Sc. degree in chemistry from the University of California, Los
Angeles, which included studies at Georg-August University, Goettingen,
Germany.
Sponsoring the prestigious CPhI Pharma Awards opens the door to consistent, long-term promotion of your company to the global biopharmaceutical industry. Partnering with the CPhI Pharma Awards also shows the industry, press, competitors and customers, that you are an industry pioneer who is among the best in the game. Benefits of sponsoring the CPhI Pharma Awards include:
Unrivalled branding – The CPhI Pharma Awards is an exceptional PR opportunity for sponsors. With prominent industry figures in attendance – attendees will include members of the awards jury and representatives of international pharma associations.
Competitive advantage – Be included in an extensive marketing and PR campaign to promote the CPhI Pharma Awards – through a wide range of on and offline channels from when you sign up until after the Awards take place.
Interested in sponsoring the CPhI Pharma Awards? Take a look at the package breakdown here.
All entries must be based on activities undertaken between 30 June 2021 – 1 August 2022.
For more information, please refer to our Entry Guide.
It may sound simple, but when you start creating your submission, please ensure that you opt for the correct category. You’d be surprised how many entries are incorrectly submitted and thus stand no chance of winning.
Once you’ve selected the correct category, carefully read the criteria distinguishing how your product or service meets each. Give yourself ample time to analyse your work and try to involve specialists who have worked on the project directly as they will have the best idea of its objectives, how it progressed and exactly what made it such a success.
When creating an award-winning entry, it’s not enough to simply fill in the entry form correctly.
We recommend trying to tell a story with your submission to really captivate the judges.
Consider key points such as:
- What is the aim of your product/service/ technology?
- What problem does it solve?
- Why is this so important?
- Which struggles did you come across along the way?
- Why has it been such a success?
- What overall effect has your product/service/ tech had?
While our judges love to hear about what you’ve achieved, there’s little use peppering your submission with bold statements that can’t be upheld.
Supporting evidence
Rather than stating for example ‘we received positive feedback’ please provide evidence – it will really strengthen your entry.
Supporting evidence could include:
1. Market data to show commercial success
2. Product information and images
3. Details of deals done, synergies delivered, and integration goals achieved
4. Documentation, such as press releases, evidence of clinical trial success, clinical study reports
5. Responses and testimonials from customers
6. Details of other Awards won, nominations or accolades
Thank you for your interest in the CPhI Pharma Awards! You can submit your entry via the link below:
The deadline for all entries is 31st May 2022. All entries must be based on activities undertaken between 30 June 2021 – 1 August 2022
It is important to show how your product or solution is innovative, not only tell. Please provide evidence of your claims, a comparison to existing products already on the market and supporting material wherever possible.
Shortlisted entries will be announced in September 2022, and the winners at an Awards ceremony on-site at CPhI Worldwide 2022 in Frankfurt on 1st November.
Good luck!
Excellence in Pharma: Packaging & Drug Delivery
Eitan Medical
Excellence in Pharma: Supply Chain, Logistics, and Distribution
Rephine Sourcing
Excellence in Pharma: Sustainability
Adalvo
Excellence in Pharma: Innovation in Response to COVID-19
Novavax
Excellence in Pharma: Finished Formulation
Clarus Therapeutics
Excellence in Pharma: API Development
Catalent, GPEx Lightning
Excellent in Pharma: Digital Innovation
Viatris
Excellence in Pharma: Regulatory Procedures and Compliance
BASF
Excellence in Pharma: Innovation in Response to COVID-19
Aprecia Pharmaceuticals
Excellence in Pharma: CEO of the Year
Lynne Ann du Toit, Eurolab (Pty)
Customer Service Team
Send an email
+31 20 245 5355
Beware of unsolicited websites and companies.
As a part of our continued commitment to the sustainability of our event, 100% of the electricity used within the venue is generated from a renewable origin.
To learn more about this please click here.
Our event has also been successfully accredited with the prestigious ISO 20121 Standard for Sustainable Event Management.
To learn more about this please click here.
Running CPhI Worldwide gives us ample opportunity to improve our impacts socially, environmentally, and economically in our host city.
We want to make a difference, and here’s how we do it.